Cellectar Biosciences, Inc. (NASDAQ:CLRB) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Sell” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
Cellectar Biosciences, Inc. (NASDAQ:CLRB) gained 3.31 Percent and closed its previous trading session at $1.25. The stock traded with the average Volume of 172.27 Million at the end of last session.
Cellectar Biosciences, Inc. (NASDAQ:CLRB) has the Market Capitalization of 19.88 Million. The Stock has its 52-week High of $3.07 and 52-Week Low of $1.12 and it touched its 52-week high on 03/14/17 and 52-Week Low on 12/01/17.
The company reported its last earnings Actual EPS of $-0.26/share. While, the analyst predicted that the company could provide an EPS of $-0.25/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.01/share which shows an Earnings Surprise of -4 Percent.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -14.05% where SMA50 and SMA200 are -21.14% and -29.69% respectively.
The company shows its Return on Assets (ROA) value of -75.4%. The Return on Equity (ROE) value stands at -88%.
Cellectar Biosciences, Inc. (NASDAQ:CLRB) currently has a Weekly Volatility of 15.16% percent while its Monthly Volatility is at 6.71% percent. While talking about Performance of the Stock, Cellectar Biosciences, Inc. currently has a Weekly performance of -10.71%, monthly performance percentage is -18.83 percent, Quarterly performance is -19.87 percent, 6 months performance shows a percent value of -26.47% and Yearly Performance is -10.71 percent.
Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in Madison, Wisconsin.